TG Therapeutics, Inc. Share Price & Technical Analysis
TGTX · $39.73 (+2.21%)
Healthcare / Biotechnology
$39.73
+2.21%
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolate…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
15% return in May, -8% avg return in past 3 year May month.
31% return in 2026, 49% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | 3% | 13% | 1% | 15% | – | – | – | – | – | – | – | 31% |
| 25 | 4% | -2% | 30% | 16% | -23% | 3% | -1% | -16% | 23% | -4% | -8% | -9% | 13% |
| 24 | -3% | 5% | -13% | -9% | -5% | 8% | 12% | 19% | -2% | 8% | 38% | -13% | 44% |
| 23 | 27% | 5% | -7% | 65% | 4% | -7% | -17% | -12% | -20% | -8% | 25% | 34% | 89% |
| 22 | -39% | -16% | -5% | -28% | -37% | -2% | 43% | 20% | -17% | -3% | 47% | 33% | -6% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.62B
P/E ratio
15.13
52W high
$44.65
52W low
$25.28
Volume
12,52,542
Beta
1.68
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is TG Therapeutics, Inc. share price today?
- TG Therapeutics, Inc. (TGTX) last traded around $39.73 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does TGTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for TGTX. Download the app for real-time alerts.
- How can I analyze TG Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.